OVID THERAPEUTICS INC (OVID)
Health Care · biotechnology / neurotherapeutics · NASDAQ
Ovid Therapeutics is a clinical-stage biopharmaceutical company developing differentiated small molecule medicines to address unmet needs in epilepsy and psychiatric disorders by targeting neuronal hyperexcitability.
What OVID THERAPEUTICS INC does
Ovid Therapeutics is a biopharmaceutical company focused on developing small molecule medicines to treat neurological and psychiatric disorders characterized by neuronal hyperexcitability. The company's pipeline includes candidates for epilepsy, including drug-resistant focal onset seizures, tuberous sclerosis complex, and infantile spasms, as well as psychosis associated with Parkinson’s disease, Lewy body dementia, and schizophrenia. Its development strategy leverages novel mechanisms, such as GABA-aminotransferase (GABA-AT) inhibition and potassium-chloride cotransporter 2 (KCC2) activation.
Recent developments
In March 2026, the company reported favorable safety and tolerability data for the 7 mg dose of OV329 and announced plans to expand its development into tuberous sclerosis complex (TSC) seizures and infantile spasms. The company also initiated a Phase 1 study for its first-in-class, oral KCC2 activator, OV4071.
From OVID THERAPEUTICS INC's filing of 2026-08-13.
Themes: epilepsy / seizure disorders, psychosis / schizophrenia, neurodegenerative diseases, CNS drug development, neuronal hyperexcitability
Fundamentals
- Price$2.36 as of 2026-10-20 close
- Market cap$461M as of 2026-08-11 (share count; price 2026-10-20)
- 1-year return+43.0% 2025-10-20 close $1.65 → 2026-10-20 close $2.36
- P/En/a negative earnings
- Net margin-240.1% FY2025, SEC XBRL
- ROE-13.3% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)+1181.3% FY2025, SEC XBRL
- Revenue CAGR (3y)+69.0% SEC XBRL
- Beta1.51 as of 2026-09-02
- Last reported earnings2026-03-18 most recent in our data — SEC EDGAR Form 8-K (Item 2.02); no newer announcement filed
How OVID compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-02
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-02
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $733000 | -$16M | -$15M | — | -$18M† | — |
| Q1 FY2026 2026-03-31 | $0 | -$18M | -$17M | — | -$14M | — |
| Q4 FY2025 2025-12-31 | $718000† | -$12M† | $10M† | — | -$10M† | $0† |
| Q3 FY2025 2025-09-30 | $132000 | -$13M | -$12M | — | -$13M† | $0† |
| Q2 FY2025 2025-06-30 | $6M | -$5M | -$5M | — | -$5M† | $0† |
| Q1 FY2025 2025-03-31 | $130000 | -$13M | -$10M | — | -$10M | $0 |
| Q4 FY2024 2024-12-31 | $76000† | -$11M† | -$9M† | — | -$10M† | $22000† |
| Q3 FY2024 2024-09-30 | $173000 | -$13M | -$14M | -$0.20 | -$15M† | -$4000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$11M
- Short-term investments$106M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How OVID THERAPEUTICS INC looks technically
OVID THERAPEUTICS INC (OVID) is trading 1.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 282 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 3 trading days ago. It is 24.0% below its highest point of the past year. Trading volume is running unusually high — about 2.2× its 30-day average, a sign of heightened interest.
Trend
9
| Distance from the 200-day | it is trading 1.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +1.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.60 | $2.60 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $2.32 | $2.32 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 28 calendar days ago — the swings before that are what the structure reading is measured on | 28 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 2.845. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 282 trading days ago — a "golden cross", a bullish long-term signal | 282 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 1.9% above | +1.9% |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend) | 23.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30) | 47.1 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($2.09 to $2.53) — its "stochastic" reading is 61 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 61.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 36 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $3.10 | $3.10 |
|---|---|---|
| From the 52-week high | it is 24.0% below its 52-week high (its highest price of the past year) | -24.0% |
| Above the 52-week low | it is 100.0% above its 52-week low (its lowest price of the past year) | +100.0% |
| Below the 52-week high | it is 24.0% below its highest point of the past year | 24.0% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $15.93 (set on 2017-05-18) | $15.93 |
| Given back of the 52-week move | over the past year its closes ranged ($1.20 to $2.96), and it has given back roughly a third of its rise from last year’s low — 34% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.82 to $1.87. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 34.1% |
| From the all-time high | it is 85.2% below its all-time high | -85.2% |
| Nearest price level | it is trading 7.5% above a support level at $2.18 — a price it turned at three times since 2026-06-11, most recently on 2026-07-31. Since 2024-10-21 it has 9 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -7.5% |
| All-time low | its lowest closing price on record is $0.243 (set on 2025-04-09) | $0.243 |
| Above the all-time low | it is 871.2% above its all-time low | +871.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 32nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1503 between its high and its low — about 6.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1503 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.13 and $2.61 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.13 – $2.37 – $2.61 |
| Typical daily range (% of price) | its price moves about 6.4% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.4% |
| Stretch from the 200-day average | it is trading 0.3 daily ranges above its 200-day average price (1.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 2.2× its 30-day average, a sign of heightened interest | 2.20× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.4% since the prior reading | -0.4% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|---|---|
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-20 0.9% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.9% |
|---|---|---|
| Gap filled | a 3.4% gap up opened on 2026-10-06 has been "filled" 10 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 10 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +9.77% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 13.2 percentage points (the stock lost 12.3% while the market gained 1.0%) | -13.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 1.2 percentage points (the stock gained 2.4% while the market gained 3.6%) | -1.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 26.9 percentage points (the stock lost 18.3% while the market gained 8.5%) | -26.9% |
| vs market, 12 months | over the past 12 months this stock beat the market by 28.5 percentage points (the stock gained 43.0% while the market gained 14.6%) | +28.5% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 8.3% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 5.9% of the share price. | -8.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 1% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $2.39 — a volume-weighted average of daily closes over 196 sessions, not a true tick-by-tick VWAP. | -1.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 10% below the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is under water. That average is $2.61 — a volume-weighted average of daily closes over 48 sessions, not a true tick-by-tick VWAP. | -9.6% |
Price levels it has turned at before
OVID last closed at $2.36 on 2026-10-20. Since 2024-10-21 it has turned at 9 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.18 | Support | 7.5% below the last close | turned there three times · 2026-06-11 to 2026-07-31 |
| $2.63 | Resistance | 11.2% above the last close | turned there twice · 2026-09-01 to 2026-09-10 |
| $2.02 | Support | 14.6% below the last close | turned there twice · 2025-10-03 to 2026-03-30 |
| $2.84 | Resistance | 20.3% above the last close | turned there twice · 2026-06-30 to 2026-09-22 |
| $1.88 | Support | 20.6% below the last close | turned there twice · 2025-12-24 to 2026-01-08 |
| $2.96 | Resistance | 25.6% above the last close | turned there three times · 2026-05-05 to 2026-08-27 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $2.85.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 16 trading days, since 2026-09-29.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Near 200-day moving-average support · Trading above the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · Unusually heavy trading volume · Broke down to a new 20-day low | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$6.00 range $4.00 – $9.00; median $5.00
Analyst estimates, as of 2026-10-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for OVID
- Consensus EPS estimate-$0.08444 next reporting period, as of 2026-10-18
- Estimate change, 30 days+$0.00413 from -$0.08857, on 2026-09-13, 35-day window
- Readings revised upward33% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company is in the early stages of clinical development and may never achieve regulatory approval or commercial success for its candidates.","Substantial history of operating losses and a requirement for significant additional capital, which may lead to shareholder dilution or the curtailment of development programs.","Dependence on the success of a narrow pipeline targeting specific neuronal mechanisms."]
What changed in the latest 10-Q
AI-assisted comparison of OVID's 10-Q filed 2026-05-12 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references Annual Report on Form 10-K for year ended December 31, 2025, filed March 18, 2026 (older filing references year ended December 31, 2024, filed March 11, 2025)
- Newer filing states company mission as 'pioneering better, gentler medicines for the brain' (older filing: 'developing small molecule medicines for brain conditions')
- Newer filing adds specific indications: drug-resistant focal onset seizures (FOS), developmental and epileptic encephalopathies (DEEs), tuberous sclerosis complex (TSC) seizures, infantile spasms (IS), and schizophrenia (older filing only mentions epilepsy and psychoses)
- Newer filing states 'Two of our programs are currently in clinical trials, and others are planned to advance into the clinic' (older filing: 'Two of our programs are in clinical trials, and a third is expected to begin a clinical trial in the second quarter of 2026')
- Newer filing reports zero royalty revenue for three months ended March 31, 2026 vs. $0.1 million for three months ended March 31, 2025
- Newer filing reports $17.0 million net loss for three months ended March 31, 2026 vs. $10.2 million for three months ended March 31, 2025
- Newer filing states $431.7 million in cumulative net proceeds from capital stock sales through March 31, 2026, including $75.1 million from October 2025 private placement and $56.2 million from March 2026 private placement
- Newer filing reports $165.6 million in cash and equivalents, $144.4 million working capital, and $338.7 million accumulated deficit as of March 31, 2026
- Newer filing adds detailed section on 'Series A Warrant Exercises' describing October 2025 warrant agreement and April 17, 2026 exercise resulting in $53.9 million gross proceeds
- Newer filing adds section on 'March 2026 Private Placement' describing Securities Purchase Agreement dated March 17, 2026, with 19,154,321 shares at $2.01 per share and Pre-Funded Warrants
- Newer filing announces March 18, 2026 approval from Human Research Ethics Committee and Australian Therapeutic Goods Administration for Phase 1 clinical trial of OV4071
- Removed:
- Older filing's statement 'Since our inception in April 2014, we have devoted substantially all of our efforts to organizing and planning our business, building our management and technical team, acquiring and developing assets and raising capital' is replaced with simpler version in newer filing
- Older filing reported $0.1 million and $6.5 million royalty and licensing revenue for three and nine months ended September 30, 2025 (not comparable periods in newer filing)
- Older filing reported $12.2 million and $27.1 million net losses for three and nine months ended September 30, 2025 (not comparable periods)
- Older filing reported $275.4 million cumulative net proceeds through September 30, 2025
- Older filing reported $25.6 million cash and $331.4 million accumulated deficit as of September 30, 2025
- Older filing's 'Private Placement' section describing October 2, 2025 transaction with Series B Preferred Stock, Series A Warrants, and Series B Warrants at $1,400 per Security with potential $175.1 million gross proceeds
- Older filing's 'Data Release' section announcing October 3, 2025 positive Phase 1 data for OV329
- Older filing's partial section on 'Significant Risks and Uncertainties' discussing global economic slowdown and geopolitical tensions
- Reworded:
- Newer filing: 'pioneering better, gentler medicines for the brain' vs. older: 'developing small molecule medicines for brain conditions'
- Newer filing: 'Our major sources of cash have been licensing revenue, proceeds from various public and private offerings of our capital stock, option exercises and interest income' (older filing does not include this sentence in the overview section)
- Newer filing specifies 'clinical trials' vs. older filing's 'in clinical trials' for two programs description
- Newer filing adds language about cash sufficiency 'will be sufficient to fund our current operating plans for at least the next 12 months from the issuance of the financial statements' vs. older filing's similar but slightly different phrasing
- Notes:
- The two filings cover different fiscal periods (March 31, 2026 vs. September 30, 2025), making some comparisons non-sequential
- The older filing appears truncated at 'Significant Risks and Uncertainties' section, limiting full comparison of later sections
- Pipeline chart references are present in both filings but chart content itself cannot be assessed from text provided
Risk Factors
- Added:
- Added bullet point: 'We are subject to numerous and varying privacy and security laws, and our failure to comply could result in penalties and reputational damage.' (changed from 'may be subject' to 'are subject') in the Summary of Select Risks section (filed 2026-05-12)
- Removed:
- Removed bullet point: 'If we fail to satisfy all applicable requirements of Nasdaq and it determines to delist our common stock, the delisting could adversely affect the market liquidity of our common stock and the market price of our common stock could decrease.' from the Summary of Select Risks section (was in filed 2025-11-12)
- Reworded:
- Changed 'We rely on third parties to conduct, supervise and monitor our preclinical studies and clinical trials...' to 'We intend to rely on third parties to conduct, supervise and monitor our preclinical studies and clinical trials...' (removed 'intend to' in newer filing, filed 2026-05-12)
- Changed 'We may be subject to numerous and varying privacy and security laws...' to 'We are subject to numerous and varying privacy and security laws...' (changed 'may be' to 'are' in newer filing, filed 2026-05-12)
- Updated financial figures from 'As of September 30, 2025, our cash, cash equivalents and marketable securities were $25.6 million and we had an accumulated deficit of $331.4 million' to 'As of March 31, 2026, our cash, cash equivalents and marketable securities were $165.6 million and we had an accumulated deficit of $338.7 million' (filed 2026-05-12)
- Notes:
- The newer filing text appears truncated at the end of the 'Risks Related to Our Financial Position and Need for Additional Capital' section, limiting full comparison of that section
- Page numbers differ between filings (34 vs 36), suggesting potential structural differences in the documents
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
Most recent open-market transaction: 2026-02-23. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about OVID's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding OVID as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 18,960,155
- Reported value $51,002,818
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about OVID's institutional holders → See what each manager we track holds →
Short interest (FINRA)
OVID had 18,948,082 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
OVID had 9.70% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.93 days to cover at the same settlement.
- Reported short interest (shares) 18,948,082
- Short interest (% of shares outstanding) 9.70%
- Prior settlement (shares) 21,151,179
- Reported change -10.42%
- Days to cover (reported) 8.93
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- UCB (UCBJY)
- Jazz Pharmaceuticals (JAZZ)
- Sage Therapeutics
- Acadia Pharmaceuticals (ACAD)
- Neurocrine Biosciences (NBIX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare OVID vs…
OVID ranks in…
Frequently asked questions
What does OVID THERAPEUTICS INC (OVID) do?
Ovid Therapeutics is a biopharmaceutical company focused on developing small molecule medicines to treat neurological and psychiatric disorders characterized by neuronal hyperexcitability. The company's pipeline includes candidates for epilepsy, including drug-resistant focal onset seizures, tuberous sclerosis complex, and infantile spasms, as well as psychosis associated with Parkinson’s disease, Lewy body dementia, and schizophrenia.
What sector is OVID THERAPEUTICS INC (OVID) in?
OVID THERAPEUTICS INC (OVID) is classified in the Health Care sector. Its industry is biotechnology / neurotherapeutics. It trades on NASDAQ.
Who are OVID THERAPEUTICS INC's (OVID) competitors?
Notable peers of OVID THERAPEUTICS INC (OVID) include UCB, Jazz Pharmaceuticals, Sage Therapeutics, Acadia Pharmaceuticals and Neurocrine Biosciences. This peer set is informational only — not financial advice.
Is OVID THERAPEUTICS INC (OVID) overbought or oversold right now?
OVID THERAPEUTICS INC (OVID) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 47, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on OVID come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.